Triazolam Chemische Eigenschaften,Einsatz,Produktion Methoden
R-S?tze Betriebsanweisung:
R11:Leichtentzündlich.
R23/24/25:Giftig beim Einatmen, Verschlucken und Berührung mit der Haut.
R36/38:Reizt die Augen und die Haut.
R39/23/24/25:Giftig: ernste Gefahr irreversiblen Schadens durch Einatmen, Berührung mit der Haut und durch Verschlucken.
S-S?tze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn m?glich, dieses Etikett vorzeigen).
S36/37:Bei der Arbeit geeignete Schutzhandschuhe und Schutzkleidung tragen.
S16:Von Zündquellen fernhalten - Nicht rauchen.
S7:Beh?lter dicht geschlossen halten.
Chemische Eigenschaften
Yellow Solid
Verwenden
Triazolam
Weltgesundheitsorganisation (WHO)
Triazolam, a benzodiazepine derivative with sedative and
hypnotic activity, was introduced in 1978 for themanagement of insomnia. It is
controlled under Schedule IV of the 1971 Convention of Psychotropic Substances.
Concern regarding the psychotropic effects of triazolam was first raised in the
Netherlands in 1979 when this compound was suspended for sale and
subsequently withdrawn by the Committee for the Evaluation of Medicines on the
basis of reports of a reversible complex of symptoms including paranoia,
depersonalization, nightmares, suicidal tendency and hyperaesthesia in patients
receiving the drug. The basis for this decision was later successfully contested by
the manufacturer and the drug was reregistered in early 1990 with a revised
product information. However, concern was regenerated elsewhere that higher
doses are associated with an unacceptable incidence of unwanted effects and the
manufacturer has eventually withdrawn 0.5 mg tablets on a worldwide basis. In 1991 the issue of the safety of triazolam was again reopened by reports of
retrograde amnesia and depression among patients taking the decreased
recommended dosages. The product information has been revised by the United
States FDA to include more rigorous cautions regarding dosage. In the Member
States of the European Communities the products have been suspended pending
further review by the EC Committee on Proprietary Medicinal Products.
Allgemeine Beschreibung
Triazolam, 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4] benzodiazepine(Halcion), has all of the characteristic benzodiazepine pharmacologicalactions. It is an ultra–short-acting hypnoticbecause it is rapidly α-hydroxylated to the 1-methyl alcohol,which is then rapidly conjugated and excreted.Consequently, it has gained popularity as sleep inducers, especiallyin elderly patients, because it causes less daytimesedation. It is metabolically inactivated primarily by hepaticand intestinal CYP3A4; therefore, coadministration withgrapefruit juice increases its peak plasma concentration by30%, leading to increased drowsiness.
Triazolam Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
